SCHEMBL23934280

SCHEMBL23934280

CN1C(=O)c2cc(N)cc(N)c2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
USP2 O75604 2/20 0.41
ATM Q13315 1/20 0.41
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
CASP3 P42574 1/20 0.36
ALDH1A1 P00352 4/20 0.36
CASP1 P29466 2/20 0.35
CASP7 P55210 2/20 0.35
BRCA1 P38398 1/20 0.35
HSD17B10 Q99714 3/20 0.34
MAPT P10636 3/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
ALOX15 P16050 1/20 0.34
APP P05067 6/20 0.33
HPGD P15428 2/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17316947 0.82 MEN1 (0.40) MEN1KMT2AUSP2ATMKEAP1
SCHEMBL7941648 0.78 MEN1 (0.40) MEN1KMT2AUSP2ATMKEAP1
SCHEMBL441644 0.75 MEN1 (0.47) MEN1KMT2AUSP2ATMKEAP1
SCHEMBL27099941 0.74 ALDH1A1 (0.41) MEN1KMT2AALDH1A1HSD17B10MAPT
SCHEMBL917833 0.72 ALDH1A1 (0.59) MEN1KMT2ANR1H2NR1H3CASP3
SCHEMBL29833030 0.72 ALDH1A1 (0.59) MEN1KMT2ANR1H2NR1H3CASP3
SCHEMBL11553071 0.72 MEN1 (0.50) MEN1KMT2AUSP2ATMKEAP1
SCHEMBL2036747 0.71 MEN1 (0.58) MEN1KMT2AUSP2ATMKEAP1
SCHEMBL8663125 0.70 ALDH1A1 (0.43) MEN1KMT2AUSP2CASP3ALDH1A1
SCHEMBL23934207 0.70 THRB (0.50) MEN1KMT2AUSP2ATMKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 MEN1 2490/4885KMT2A 2003/4885USP2 2442/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 MEN1 2490/4885KMT2A 2003/4885USP2 2442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.